Nordic Life Science
Pharma
Latest Pharma News
Before Christmas the company announces that the transformation to focus the company’s internal resources on its clinical development projects has now been completed. Redundancies, mainly within research and administration, are
The Danish biotech company has been awarded an investment of 3.6 mEUR from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR). An additional
AstraZeneca’s partner Ironwood Pharmaceuticals has received marketing authorization from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with
The Food and Drug Administration (FDA) and the Central Ethics Committee in the United States have accepted Xbranes IND application for initiation of the Xplore trial, a phase III trial
The U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under the ongoing contract for freeze-dried MVA-BN smallpox vaccine. The option, valued at USD 44 million, will
The company has announced organizational changes, including the development of R&D and commercial units in its biopharmaceuticals area and in oncology. In addition, three senior executives leaves the company and
Clinical trials
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore
The company initiates a phase II-study (proof of concept-study) with the compound Lu AF11167 to confirm its potential as treatment
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available
The Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients
The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015
The company has submitted its first national Clinical Trial Application (CTA) to the Food and Drug Administration (FDA) in the US
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase
Nordic Nanovector announces that updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-lilotomab-satetraxetan) in patients with
The company has presented a comprehensive analysis of monotherapy data from its BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor
LIDDS adds two major university clinics in Lithuania to its ongoing Phase IIb study, the National Cancer Institute in Vilnius
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501
Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from
The first patient has been dosed in a Phase 2 study evaluating the company’s cancer immunotherapy, BN-Brachyury, and radiation in
The company announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin (177Lu-satetraxetan-lilotomab) in combination with
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
“It is with great regret and sadness we announce this very tragic and unexpected information,” says the Board of Directors,
In an interview in Nordic Life Science, the Head of AstraZeneca’s Oncology Business unit, shared his insights on current drug
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments